Denali Therapeutics Inc. Research and Development Expense
Denali Therapeutics Inc. (DNLI) reported Research and Development Expense of $97.02 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ResearchAndDevelopmentExpense · last filed 2026-08-06
- Denali Therapeutics Inc. research and development expense for the quarter ending 2026-06-30 was $97.02M, a 5.53% decline year-over-year.
- Denali Therapeutics Inc. research and development expense for the quarter ending 2026-03-31 was $103.85M, a 10.65% decline year-over-year.
- Denali Therapeutics Inc. research and development expense for the quarter ending 2025-12-31 was $97.91M, a 1.89% decline year-over-year.
- Denali Therapeutics Inc. research and development expense for the quarter ending 2025-09-30 was $101.95M, a 3.78% increase year-over-year.
- Denali Therapeutics Inc. research and development expense for fiscal 2025 was $418.78M, a 5.63% increase from fiscal 2024.
- Denali Therapeutics Inc. research and development expense for fiscal 2024 was $396.44M, a 6.47% decline from fiscal 2023.
- Denali Therapeutics Inc. research and development expense for fiscal 2023 was $423.88M, a 18.16% increase from fiscal 2022.
- Denali Therapeutics Inc. research and development expense for fiscal 2022 was $358.73M, a 35.19% increase from fiscal 2021.
| Period end | Research and Development Expense 3 month | Research and Development Expense 6 month | Research and Development Expense 9 month | Research and Development Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $97.02M 10-Q · filed 2026-08-06 | $200.87M 10-Q · filed 2026-08-06 | $298.77M derived: sum of 3 quarters · filed 2026-08-06 | $400.72M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $103.85M 10-Q · filed 2026-05-07 | $201.75M derived: sum of 2 quarters · filed 2026-05-07 | $303.70M derived: sum of 3 quarters · filed 2026-05-07 | $406.40M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $97.91M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $199.85M derived: sum of 2 quarters · filed 2026-02-26 | $302.55M derived: sum of 3 quarters · filed 2026-08-06 | $418.78M 10-K · filed 2026-02-26 |
| 2025-09-30 | $101.95M 10-Q · filed 2025-11-06 | $204.65M derived: sum of 2 quarters · filed 2026-08-06 | $320.87M 10-Q · filed 2025-11-06 | $420.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $102.70M 10-Q · filed 2026-08-06 | $218.92M 10-Q · filed 2026-08-06 | $318.71M derived: sum of 3 quarters · filed 2026-08-06 | $416.95M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $116.23M 10-Q · filed 2026-05-07 | $216.01M derived: sum of 2 quarters · filed 2026-05-07 | $314.25M derived: sum of 3 quarters · filed 2026-05-07 | $405.65M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $99.79M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $198.03M derived: sum of 2 quarters · filed 2026-02-26 | $289.42M derived: sum of 3 quarters · filed 2026-02-26 | $396.44M 10-K · filed 2026-02-26 |
| 2024-09-30 | $98.24M 10-Q · filed 2025-11-06 | $189.64M derived: sum of 2 quarters · filed 2025-11-06 | $296.65M 10-Q · filed 2025-11-06 | $404.46M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $91.40M 10-Q · filed 2025-08-11 | $198.41M 10-Q · filed 2025-08-11 | $306.22M derived: sum of 3 quarters · filed 2026-02-26 | $395.95M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $107.02M 10-Q · filed 2025-05-06 | $214.82M derived: sum of 2 quarters · filed 2026-02-26 | $304.56M derived: sum of 3 quarters · filed 2026-02-26 | $402.08M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $107.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $197.54M derived: sum of 2 quarters · filed 2026-02-26 | $295.06M derived: sum of 3 quarters · filed 2026-02-26 | $423.88M 10-K · filed 2026-02-26 |
| 2023-09-30 | $89.74M 10-Q · filed 2024-11-06 | $187.26M derived: sum of 2 quarters · filed 2024-11-06 | $316.07M 10-Q · filed 2024-11-06 | $408.18M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $97.52M 10-Q · filed 2024-08-01 | $226.34M 10-Q · filed 2024-08-01 | $318.45M derived: sum of 3 quarters · filed 2025-02-27 | $406.23M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $128.82M 10-Q · filed 2024-05-07 | $220.93M derived: sum of 2 quarters · filed 2025-02-27 | $308.71M derived: sum of 3 quarters · filed 2025-02-27 | $401.45M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $92.11M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | $179.90M derived: sum of 2 quarters · filed 2025-02-27 | $272.63M derived: sum of 3 quarters · filed 2025-02-27 | $358.73M 10-K · filed 2025-02-27 |
| 2022-09-30 | $87.79M 10-Q · filed 2023-11-07 | $180.52M derived: sum of 2 quarters · filed 2023-11-07 | $266.62M 10-Q · filed 2023-11-07 | $334.50M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-06-30 | $92.74M 10-Q · filed 2023-08-08 | $178.84M 10-Q · filed 2023-08-08 | $246.71M derived: sum of 3 quarters · filed 2024-02-28 | $318.27M derived: sum of 4 quarters · filed 2024-02-28 |
| 2022-03-31 | $86.10M 10-Q · filed 2023-05-08 | $153.97M derived: sum of 2 quarters · filed 2024-02-28 | $225.53M derived: sum of 3 quarters · filed 2024-02-28 | $291.24M derived: sum of 4 quarters · filed 2024-02-28 |
| 2021-12-31 | $67.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | $139.44M derived: sum of 2 quarters · filed 2024-02-28 | $205.15M derived: sum of 3 quarters · filed 2024-02-28 | $265.35M 10-K · filed 2024-02-28 |
| 2021-09-30 | $71.56M 10-Q · filed 2022-11-03 | $137.27M derived: sum of 2 quarters · filed 2022-11-03 | $197.48M 10-Q · filed 2022-11-03 | $252.22M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-06-30 | $65.71M 10-Q · filed 2022-08-08 | $125.92M 10-Q · filed 2022-08-08 | $180.66M derived: sum of 3 quarters · filed 2023-02-27 | $234.37M derived: sum of 4 quarters · filed 2023-02-27 |
| 2021-03-31 | $60.21M 10-Q · filed 2022-05-05 | $114.95M derived: sum of 2 quarters · filed 2023-02-27 | $168.65M derived: sum of 3 quarters · filed 2023-02-27 | $221.81M derived: sum of 4 quarters · filed 2023-02-27 |
| 2020-12-31 | $54.74M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $108.45M derived: sum of 2 quarters · filed 2023-02-27 | $161.60M derived: sum of 3 quarters · filed 2023-02-27 | $212.62M 10-K · filed 2023-02-27 |
| 2020-09-30 | $53.70M 10-Q · filed 2021-11-04 | $106.86M derived: sum of 2 quarters · filed 2021-11-04 | $157.87M 10-Q · filed 2021-11-04 | $209.42M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-06-30 | $53.15M 10-Q · filed 2021-08-04 | $104.17M 10-Q · filed 2021-08-04 | $155.72M derived: sum of 3 quarters · filed 2022-02-28 | $208.26M derived: sum of 4 quarters · filed 2022-02-28 |
| 2020-03-31 | $51.02M 10-Q · filed 2021-05-05 | $102.57M derived: sum of 2 quarters · filed 2022-02-28 | $155.11M derived: sum of 3 quarters · filed 2022-02-28 | $207.00M derived: sum of 4 quarters · filed 2022-02-28 |
| 2019-12-31 | $51.55M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | $104.09M derived: sum of 2 quarters · filed 2022-02-28 | $155.98M derived: sum of 3 quarters · filed 2022-02-28 | $193.38M 10-K · filed 2022-02-28 |
| 2019-09-30 | $52.54M 10-Q · filed 2020-11-05 | $104.43M derived: sum of 2 quarters · filed 2020-11-05 | $141.83M 10-Q · filed 2020-11-05 | $181.74M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-06-30 | $51.88M 10-Q · filed 2020-08-07 | $89.29M 10-Q · filed 2020-08-07 | $129.20M derived: sum of 3 quarters · filed 2021-02-26 | $159.52M derived: sum of 4 quarters · filed 2021-02-26 |
| 2019-03-31 | $37.40M 10-Q · filed 2020-05-07 | $77.31M derived: sum of 2 quarters · filed 2021-02-26 | $107.63M derived: sum of 3 quarters · filed 2021-02-26 | $159.77M derived: sum of 4 quarters · filed 2021-02-26 |
| 2018-12-31 | $39.91M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | $70.23M derived: sum of 2 quarters · filed 2021-02-26 | $122.36M derived: sum of 3 quarters · filed 2021-02-26 | $143.18M 10-K · filed 2021-02-26 |
| 2018-09-30 | $30.32M 10-Q · filed 2019-11-06 | $82.45M derived: sum of 2 quarters · filed 2019-11-06 | $103.27M 10-Q · filed 2019-11-06 | $121.75M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $52.13M 10-Q · filed 2019-08-06 | $72.95M 10-Q · filed 2019-08-06 | $91.42M derived: sum of 3 quarters · filed 2020-02-27 | $109.94M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $20.82M 10-Q · filed 2019-05-08 | $39.29M derived: sum of 2 quarters · filed 2020-02-27 | $57.80M derived: sum of 3 quarters · filed 2020-02-27 | $76.81M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $18.47M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $36.99M derived: sum of 2 quarters · filed 2020-02-27 | $55.99M derived: sum of 3 quarters · filed 2020-02-27 | $74.46M 10-K · filed 2020-02-27 |
| 2017-09-30 | $18.52M 10-Q · filed 2018-11-08 | $37.52M derived: sum of 2 quarters · filed 2018-11-08 | $55.99M 10-Q · filed 2018-11-08 | |
| 2017-06-30 | $19.00M 10-Q · filed 2018-08-09 | $37.47M 10-Q · filed 2018-08-09 | ||
| 2017-03-31 | $18.47M 10-Q · filed 2018-05-11 | |||
| 2016-12-31 | $75.70M 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |